Response to: Comment on "Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)".
作者信息
Galarza Fortuna Gliceida M, Swami Umang, Gupta Sumati
机构信息
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA
出版信息
J Immunother Cancer. 2025 May 26;13(5):e012378. doi: 10.1136/jitc-2025-012378.
Abstract
摘要
相似文献
1
Response to: Comment on "Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)".对《关于纳武利尤单抗用于局部肌层浸润性尿路上皮癌放化疗辅助治疗：一项多中心、单臂、II期研究者发起试验（NEXT）的初步分析》评论的回应
J Immunother Cancer. 2025 May 26;13(5):e012378. doi: 10.1136/jitc-2025-012378.
2
Comment on "Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)".关于“纳武利尤单抗用于局部肌层浸润性尿路上皮癌放化疗的辅助治疗：一项多中心、单臂、II期研究者发起试验（NEXT）的初步分析”的评论
J Immunother Cancer. 2025 Apr 1;13(4):e012084. doi: 10.1136/jitc-2025-012084.
3
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT).纳武单抗用于局部肌肉浸润性尿路上皮癌放化疗辅助治疗：一项多中心、单臂、II期研究者发起试验（NEXT）的初步分析
J Immunother Cancer. 2025 Mar 18;13(3):e010572. doi: 10.1136/jitc-2024-010572.
4
Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT).根治性膀胱切除术联合免疫治疗局部晚期膀胱癌的放射治疗 - 一项前瞻性、单臂、多中心 II 期试验（RACE IT）的研究方案。
BMC Cancer. 2020 Jan 3;20(1):8. doi: 10.1186/s12885-019-6503-6.
5
Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial.伊匹单抗和纳武单抗诱导治疗后行巩固性放化疗作为尿路上皮膀胱癌的器官保留治疗：INDIBLADE试验的研究方案
Front Oncol. 2023 Aug 29;13:1246603. doi: 10.3389/fonc.2023.1246603. eCollection 2023.
6
A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial.一项新辅助 Sasanlimab 和立体定向体部放疗作为顺铂禁忌型 MIBC 疫苗的 II 期临床试验：RAD VACCINE MIBC 试验。
Future Oncol. 2022 Aug;18(25):2771-2781. doi: 10.2217/fon-2022-0380. Epub 2022 Jun 15.
7
Current status and future perspectives of immunotherapy against urothelial and kidney cancer.免疫治疗在膀胱癌和肾癌中的现状与展望。
Jpn J Clin Oncol. 2021 Oct 5;51(10):1481-1492. doi: 10.1093/jjco/hyab121.
8
Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.新辅助免疫治疗在膀胱癌中的作用及结果。
Eur Urol Oncol. 2020 Dec;3(6):728-738. doi: 10.1016/j.euo.2020.06.009. Epub 2020 Nov 8.
9
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.纳武利尤单抗辅助治疗与安慰剂用于肌肉浸润性尿路上皮癌。
N Engl J Med. 2021 Jun 3;384(22):2102-2114. doi: 10.1056/NEJMoa2034442.
10
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.在铂类化疗后晚期移行细胞癌患者中使用纳武利尤单抗联合或不联合伊匹木单抗的定制免疫治疗方法（TITAN-TCC）：一项多中心、单臂、2期试验。
Lancet Oncol. 2023 Apr;24(4):347-359. doi: 10.1016/S1470-2045(23)00053-0. Epub 2023 Feb 28.
本文引用的文献
1
Comment on "Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)".关于“纳武利尤单抗用于局部肌层浸润性尿路上皮癌放化疗的辅助治疗：一项多中心、单臂、II期研究者发起试验（NEXT）的初步分析”的评论
J Immunother Cancer. 2025 Apr 1;13(4):e012084. doi: 10.1136/jitc-2025-012084.
2
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT).纳武单抗用于局部肌肉浸润性尿路上皮癌放化疗辅助治疗：一项多中心、单臂、II期研究者发起试验（NEXT）的初步分析
J Immunother Cancer. 2025 Mar 18;13(3):e010572. doi: 10.1136/jitc-2024-010572.
3
Key considerations to reduce or address respondent burden in patient-reported outcome (PRO) data collection.减少或解决患者报告结局（PRO）数据收集过程中受访者负担的关键考虑因素。
Nat Commun. 2022 Oct 12;13(1):6026. doi: 10.1038/s41467-022-33826-4.
4
Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.肿瘤无细胞 DNA 拷贝数不稳定性预测免疫治疗的反应。
Clin Cancer Res. 2017 Sep 1;23(17):5074-5081. doi: 10.1158/1078-0432.CCR-17-0231. Epub 2017 Mar 20.
Zotero 插件